-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Obesity is an important factor for shortening life expectancy, and it is also an important risk factor for chronic diseases such as diabetes and hypertension.
Diabetes bariatric surgery can reduce the long-term relative mortality risk of obese people, but the mortality rate of obese people is still higher than that of the general population.
The results are encouraging-in general, more than half of the patients lost more than 15% of their weight once a week with semaglutide, and nearly one-third of the patients lost more than 20% of their weight.
The results are encouraging-in general, more than half of the patients lost more than 15% of their weight once a week with semaglutide, and nearly one-third of the patients lost more than 20% of their weight.
Semaglutide is a GLP-1 receptor agonist, which can stimulate the production of insulin, inhibit the secretion of glucagon, reduce appetite, and increase satiety.
The study still compared the impact of weekly subcutaneous injection of 2.
management
Participants were randomized (2:1) to receive Somalut 2.
The results showed that among 611 random participants (495 women [81.
In the 68th week, compared with the placebo group, the average weight was reduced by 5.
More patients in the Somaglutide treatment group reached the goal of losing ≥5% of their baseline body weight More patients in the Somaglut treatment group reached the goal of ≥5% of baseline weight reduction A higher proportion of patients in the Somaglutide group had a weight loss Reduce at least 10% (75.
For this reason, combined with the previous results on NEJM, we have every reason to believe that in overweight or obese adults, once a week subcutaneous injection of Somalut can make obese patients lose more weight within 68 weeks.
It is hoped that the drug will be approved by the US FDA as soon as possible to help more patients control their weight and get rid of the troubles of obesity.
It is hoped that the drug will be approved by the US FDA as soon as possible to help more patients control their weight and get rid of the troubles of obesity.
references:
Wadden TA, et al.
com/journals/jama/fullarticle/2777025" target="_blank" rel="noopener">Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Leave a message here
